Navigation Links
EMD Serono Launches Landmark Patient Registry for Egg Freezing
Date:11/7/2008

egistry will help support the goals of the ASRM's Practice Committee, which called for more studies on the health outcomes of children born from various egg freezing techniques in 2006.

"We need to validate the safety and efficacy of egg freezing for it to become a more widely available option for women who for a variety of reasons would like to preserve their fertility. The HOPE Registry is an exciting vehicle that will assist us in the evidence-gathering process and will facilitate the furthering of the science and the acceptance of oocyte cryopreservation as an effective clinical practice," said Dr. Alan Copperman, Director of the Division of Reproductive Endocrinology and Vice-Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at Mount Sinai Medical Center in New York, and co-director of Reproductive Medicine Associates of New York.

One patient group that has benefited significantly from egg freezing is women who have been diagnosed with certain types of cancer during their reproductive years and wish to preserve their fertility before cancer treatments. This is one of the few viable options for these women, who require chemotherapy and/or radiotherapy treatments that may cause infertility and premature ovarian failure depending on their cancer diagnosis.

Lindsay Nohr Beck is a cancer survivor who used oocyte cryopreservation before starting chemotherapy. She is the Founder and Executive Director of Fertile Hope, a nonprofit organization dedicated to providing reproductive information and support to cancer patients and survivors.

"Each year, more than 140,000 people are diagnosed with cancer during their childbearing years," said Ms. Nohr Beck. "The HOPE Registry is expected to substantiate egg freezing as an option, so that fertility is one less obstacle these patients may need to overcome in fulfilling their dreams of becoming a parent and living the lives they imagined prior to their cancer diagnosis." <
'/>"/>

SOURCE EMD Serono, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
2. Merck Serono Named as a Top Employer by Science Magazine
3. EMD Serono Named as a Top Employer by Science Magazine
4. EMD Serono to Adopt Revised and Strengthened PhRMA Code
5. EMD Serono Announces Planned Investment of $50 Million in Research Center in Massachusetts
6. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
7. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
8. SkinMedica Launches TNS Essential Serum(TM)
9. Genesis Pharmaceuticals Launches New Corporate Website
10. Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
11. HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6
Breaking Biology News(10 mins):Canna can: Ornamental eliminates pollutants from stormwater runoff 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Berkeley Lab researchers participate in Homeland Security study of subway airflow 2Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 53573 1Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 53573 2Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 53573 3Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 53573 4Restoring a natural root signal helps to fight a major corn pest 9462 1Restoring a natural root signal helps to fight a major corn pest 9462 2Restoring a natural root signal helps to fight a major corn pest 9462 3Consumer Reports Survey 3A HMOs Beat PPOs on Cost Customer Support and Billing Services 53567 1Consumer Reports Survey 3A HMOs Beat PPOs on Cost Customer Support and Billing Services 53567 2Consumer Reports Survey 3A HMOs Beat PPOs on Cost Customer Support and Billing Services 53567 3Consumer Reports Survey 3A HMOs Beat PPOs on Cost Customer Support and Billing Services 53567 4Consumer Reports Survey 3A HMOs Beat PPOs on Cost Customer Support and Billing Services 53567 5